Some GLP-1 antagonists can also help treat obesity
Placebo condition was removed, as THC concentrations were steady, as expected, during the placebo sessions
This combined approach supports long-term weight management by fostering healthier habits and coping strategies
Someone who tried semaglutide but stopped due to severe nausea could attempt Thrive GLP-1 for gentler effects, accepting reduced effectiveness in exchange for better tolerability
47 Visceral fat accumulation in patients with obesity causes a number of changes (oxidative stress, activation of the RAAS and gut dysbiosis), resulting in insulin resistance, increased vascular stiffness, T2D, dyslipidaemia, hypertension, coronary atherosclerosis and, ultimately, HFpEF